We are in the age of discovery, seizing a unique moment in time. Every generation experiences a breakthrough that alters the world. Technology has transformed virtually every aspect of our lives, and now it’s healthcare’s turn. aMoon is here to accelerate this transformation.
and entrepreneurs to
build great companies
and accelerate cure.
- In Hebrew, aMoon אמון means Trust. It’s what we stand for.
- A moonshot is an extremely ambitious project or mission that is nearly impossible to achieve.
- Where others hear moonshot and see the impossible, we seek out moonshots and see what is possible.
We partner with exceptional entrepreneurs who harness groundbreaking science and technology to transform healthcare. Through aMoon Velocity and aMoon Growth, we invest in early and late-stage companies pursuing disruptive, cutting-edge solutions for high unmet medical needs. We build bridges between our portfolio companies and global tech, finance and medical research hubs to enable entrepreneurs to turn their vision into reality.
aMoon Alpha is an in-house team dedicated to strengthening our portfolio Companies’ execution capabilities and unlocking additional value creation opportunities. By leveraging our internal capabilities, scale and global network, we don’t simply hope for the best, we deliver it.
We operate a global talent engine that
identifies and engages exceptional
entrepreneurs, managerial candidates
and top advisors, efficiently matching
them with the ongoing needs
of our portfolio companies.
Our Bridges program connects aMoon portfolio companies with key
ecosystem players in the healthcare field. Through these relationships,
entrepreneurs are able to sharpen their understanding of market
needs, refine product market-fit, and execute operational plans with
greater impact and speed. We help our companies build partnerships
with top private and public co-investors, Wall Street leaders, research
institutions and payers and provider networks, as well as the largest
Biopharma, MedTech and Tech corporations in the world.
We have built and are continually refining a set
of proprietary research and intelligence sources
to help our investment teams stay on top of
emerging trends, create robust investment
theses, and assist our portfolio companies with
the depth of their market insights.
We are a team of scientists, physicians,
entrepreneurs and investors with global
experience who have dedicated our lives to
science, medicine, technology, and progress.
Serial entrepreneurs Marius Nacht and
Dr. Yair Schindel established aMoon to seize this
unique moment in time, when biology and
technology are converging at an unprecedented
rate. Armed with a deep understanding of the
challenges facing entrepreneurs and a passion
to make healthcare more affordable, higher
quality and to improve access to care,
we partner with outstanding CEOs who are
passionate about transforming healthcare.
- aMoon Growth
- aMoon Velocity
Cision PR Newswire
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
June 16, 2021
Ibex Medical Analytics granted 'Breakthrough Device Designation' by the FDA, fast-tracking its approval
June 9, 2021
December 15, 2019
Driving to Target: How Adicet Bio’s Novel Therapy Addresses Key Drawbacks in Immune-Oncology